Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG)

Stefanie Graeter; Hans-Uwe Simon; Stephan von Gunten

doi:10.1016/j.phrs.2019.02.007

Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG)

Pharmacol Res. 2020 Apr:154:104168. doi: 10.1016/j.phrs.2019.02.007. Epub 2019 Feb 6.

Authors

Stefanie Graeter¹, Hans-Uwe Simon², Stephan von Gunten³

Affiliations

¹ Institute of Pharmacology, University of Bern, Bern, Switzerland.
² Institute of Pharmacology, University of Bern, Bern, Switzerland; Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia.
³ Institute of Pharmacology, University of Bern, Bern, Switzerland. Electronic address: stephan.vongunten@pki.unibe.ch.

PMID: 30738127
DOI: 10.1016/j.phrs.2019.02.007

Abstract

Granulocytes are key effector cells of the innate immune system that cause substantial by-stander tissue damage in a broad range of inflammatory disorders. Specific antibodies with the potential to regulate granulocyte survival are present in polyclonal intravenous immunoglobulin (IVIG) preparations and may contribute to the anti-inflammatory effects of high-dose IVIG therapy. Here, we discuss idiosyncratic characteristics of antibodies to FAS and Siglecs contained in IVIG pertaining to granulocyte death regulation and highlight implications for research and clinical practice.

Keywords: Eosinophils; FAS; Granulocytes; High-dose IVIG; IVIG; Immunomodulation; Intravenous immunoglobulin; Neutrophils; Siglec-8; Siglec-9.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cell Death / drug effects
Granulocytes / drug effects*
Humans
Immunoglobulins, Intravenous / adverse effects*
Models, Animal

Substances

Immunoglobulins, Intravenous